JKJaideep Kapur

Jaideep Kapur

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaideep Kapur has a total of 420 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Distinct clinical phenotypes of late onset and early onset epilepsies

    by Syeda Amrah Hashmi, Mark Quigg, Muhammad Asjad Abbas, Gurleen Kaur, Jaideep Kapur, Farsam Abbas, Carol Manning, Ifrah Zawar

    Objective: Despite representing the most common and fastest growing form of epilepsy in older adults, the clinical features of late onset epilepsy (LOE) and how it differs from early onset epilepsy (EOE) remain largely underexplored. Therefore, we evaluate the characteristics and risk factors of LOE compared to EOE. Methods: In this single‐center, retrospective study, individuals with clinically diagnosed epilepsy presenting at the University of Virginia from July 1, 2024 to September 30, 2024 were included. A cohort of older adults was identified and divided into two groups: LOE if epilepsy onset occurred at ≥60 years and EOE if epilepsy onset was before 60 years. Univariable analysis was conducted using Pearson chi‐squared, Fisher exact, or Wilcoxon rank‐sum tests. Multivariable logistic regression was performed to identify risk factors associated with LOE. Results: A total of 326 individuals were included (LOE: n = 97, EOE: n = 229). Overall, 173 (53%) were women. Age at epilepsy onset was higher in LOE (LOE: 67 years [interquartile range (IQR) = 63–73], EOE: 32 years [IQR = 13–50], p < .001). LOE subjects were more likely to be employed/retired than unemployed/disabled (93% vs. 59%, p < .001), to have focal epilepsy (93% vs. 78%, p = .002), and to demonstrate cognitive impairment (32% vs. 16%, p = .001). Cognitive impairment developed after epilepsy onset in the majority of individuals in both groups (LOE: 82%, EOE: 93%). Among the 284 (87%) individuals who underwent electroencephalography, epileptiform discharges or seizures were less frequent in LOE (31% vs. 53%, p < .001). On multivariable analysis, intracranial hemorrhage (odds ratio [OR] = 2.85, 95% confidence interval [CI] = 1.00–8.24, p = .049), intracranial infarction (OR = 2.93, 95% CI = 1.30–6.70, p = .010), current alcohol use (OR = 4.70, 95% CI = 2.22–10.16, p < .001), former alcohol use (OR = 2.31, 95% CI = 1.18–4.55, p = .015), higher medical comorbidity burden measured by Charlson Comorbidity Index (OR = 1.40, 95% CI = 1.21–1.63, p < .001), and lower body mass index (OR = .95, 95% CI = .90–1.00, p = .045) were independently associated with LOE. LOE also demonstrated significantly less temporal lobe involvement (26% vs. 38%, p = .034), a lower lifetime seizure burden (>10 lifetime‐seizures: 41% vs. 80%, p < .001), lower rate of drug‐resistant‐epilepsy (18% vs. 57%, p < .001), less prior exposure to antiseizure medications (ASMs; .65 ± .71 vs. 1.43 ± 1.92, p < .001), and less use of older generation and adjunctive ASMs compared with EOE. Significance: EOE and LOE represent distinct clinical phenotypes. LOE is associated with greater focal epilepsy, cerebrovascular disease (stroke and hemorrhage), cognitive impairment, and overall higher medical comorbidity burden. Conversely, EOE reflects an epileptogenic disorder characterized by long‐standing temporal lobe involvement, drug resistance, and higher ASM exposure. Recognition of these distinctions may improve individualized diagnostic evaluation, cognitive screening, risk stratification, and therapeutic decision‐making.

  • Open Access

    The Burden of Epilepsy: The Contribution of Seizures (AES 2025 Presidential Symposium)

    by Jenny Downs, Anne T. Berg, Louis T. Dang, Jaideep Kapur, Carrie R. McDonald, Howard P. Goodkin

  • Open Access

    People Powering Change: The Movement for a National Plan for Epilepsy

    by Joyce Bender, Beth Dean, Howard P. Goodkin, Jaideep Kapur, Fred A. Lado, Daniel H. Lowenstein, Amanda Mitchell, Jack M. Parent, Karen Utley, Laura Weidner

  • Open Access

    β‐Hydroxybutyrate reduces neuronal excitability via GIRK channels

    by Soudabeh Naderi, John Williamson, Jhanvi Patel, Samikksha Kumar, Huayu Sun, Lucy Dang Nguyen, Katarzyna RęKawek, Ifrah Zawar, Jaideep Kapur

    Objective: The ketogenic diet is used to treat drug‐resistant epilepsy, yet the molecular mechanisms coupling metabolic state to seizure suppression remain understudied. β‐Hydroxybutyrate (β‐HB), a principal ketone body, exerts antiseizure effects, yet its downstream ionic mechanisms remain unclear. Methods: We used 69 C57BL/6 mice, including males and females (4‐week‐old for ex vivo electrophysiology and calcium imaging and 8‐week‐old for in vivo seizure experiments). β‐HB or saline was administered after the onset of status epilepticus, induced in mice by continuous hippocampal stimulation. Intrinsic excitability and excitatory synaptic currents on hippocampal granule cells were measured using the patch clamp technique. Calcium imaging was performed after viral delivery of a genetically encoded calcium indicator into the hippocampus. Results: In vivo, β‐HB rapidly reduced the duration of status epilepticus. At the cellular level, patch‐clamp recordings showed that β‐HB hyperpolarized dentate granule cells (DGCs) increased action potential threshold and reduced firing frequency. Moreover, β‐HB suppressed excitatory synaptic transmission onto DGCs. At the network‐level, β‐HB perfusion significantly decreased DGC population activity by reducing neuronal excitability and excitatory synaptic currents. Mechanistically, pharmacological blockade of G protein‐gated inwardly rectifying potassium (GIRK) channels prevents the β‐HB‐induced suppression of DGC intrinsic excitability, excitatory synaptic transmission, and population‐level activity. In contrast, inhibition of adenosine triphosphate‐sensitive potassium channels had no detectable impact on β‐HB‐mediated modulation of DGC intrinsic excitability or network responses. Significance: These findings identify GIRK channels as a key downstream effector of β‐HB signaling, providing a mechanistic link between ketogenic states and neuronal excitability, revealing a new mechanistic target for ketogenic therapies.

  • Open Access

    Histopathological Evidence of Neurodegenerative Pathology in Epilepsy: A Systematic Review

    by Syeda Amrah Hashmi, Aleksander Luniewski, Vanessa Smith, Matthew McCord, Jaideep Kapur, Mark Quigg, Catherine Joshua, Ifrah Zawar

    Epilepsy affects > 50 million people worldwide and is associated with a disproportionate burden of cognitive impairment. Emerging evidence suggests that neurodegenerative proteinopathies, particularly hyperphosphorylated tau (p‐tau) and amyloid‐β (Aβ), may contribute to cognitive dysfunction in people with epilepsy (PWE), even in the absence of dementia. However, the prevalence, distribution, and clinical significance of these proteins in epilepsy remain unclear. We conducted a systematic review of neuropathological studies examining neurodegenerative pathology in PWE without primary neurodegenerative disease. The review followed PRISMA guidelines and was registered with PROSPERO (CRD42024612990). A search of PubMed/MEDLINE, Ovid MEDLINE, Ovid Embase, and the Cochrane was performed from database inception to 7/8/2024. Eligible studies included human observational studies, case series, and post‐mortem or surgical pathology assessing p‐tau, amyloid, TDP‐43, or related proteinopathies in PWE. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Forty‐two studies met the inclusion criteria. Most studies involved drug‐resistant temporal lobe epilepsy (TLE) with hippocampal sclerosis. P‐Tau was the most consistently reported finding, identified across multiple epilepsy types with a prevalence ranging from 3%–95%. Amyloid was detected less consistently but occurred in both temporal and extratemporal epilepsies. Several studies reported associations between p‐tau burden and seizure frequency, epilepsy duration, and cognitive impairment, particularly in mesial TLE, although findings were heterogeneous. Neurodegenerative pathology, especially p‐tau, is frequently observed in epilepsy and may represent a biological link between seizures, hyperexcitability, and cognition. These findings suggest that epilepsy may intersect with neurodegenerative mechanisms and underscore the need for studies integrating neuropathology, biomarkers, and cognitive outcomes.


  • Open Access

    Mesial temporal shape asymmetry as a neuro-imaging correlate of epilepsy in mild cognitive impairment and dementia

    by Ifrah Zawar, Shen Zhu, Mark Quigg, Jaideep Kapur, Alice D Lam, Rani A Sarkis, Anelyssa D’ABreu, Carol Manning, P Thomas Fletcher

    Epilepsy is a common comorbidity of Alzheimer’s disease (AD) and related dementias (ADRD). Both epilepsy and ADRD affect the mesial temporal structures in volume and morphology. Nonetheless, mesial temporal shape and volume asymmetry remain understudied in persons with dementia and mild cognitive impairment, collectively called persons with cognitive impairment (PWCI) and co-morbid epilepsy. We investigated hippocampal and amygdalar left-to-right shape and volume asymmetry in AD (AD_Epi) and non-AD (nonAD_Epi) with co-morbid epilepsy. This multicentre study included participants from 39 US Alzheimer’s disease centres from 9/2005 to 12/2021. We categorized participants into group 1: PWCI with epilepsy (subclassified into AD_Epi and nonAD_Epi); group 2: PWCI without epilepsy (subclassified into AD_NoEpi and nonAD_NoEpi); and group 3: healthy controls (HC). We used a fixed-ratio, optimal propensity score matching to match group 1 participants to groups 2 and 3. Matching was based on age, sex and type of dementia (AD versus nonAD) for group 2 and age and sex for group 3. We used FreeSurfer for MRI segmentation of hippocampi and amygdalae. For volume asymmetry, we subtracted the right volume from the left and divided it by the total volume of the structure (right + left). For shape asymmetry, we calculated a 512-point shape model using left and flipped right hippocampi and, similarly, a 256-point shape model for amygdalae. Next, we calculated the point-by-point shape asymmetry between left and right hippocampi and amygdalae in a normal direction for each participant. Multivariable linear models were used to compare volume and shape asymmetry among groups after adjusting for age, sex, total intracranial volume and dementia severity. We compared AD_Epi versus AD_NoEpi, nonAD_Epi versus nonAD_NoEpi, AD_Epi versus HC, nonAD_Epi versus HC, AD_NoEpi versus HC and nonAD_NoEpi versus HC. Analyses were adjusted for multiple comparisons. A total of 703 participants were included [391(55.62%) female, average age: 70.78 years]. These included 35 AD_Epi, 28 nonAD_Epi, 183 AD_NoEpi, 137 nonAD_NoEpi and 320 HC. For shape analyses, AD_Epi showed greater left-to-right asymmetry (Left smaller than right) in hippocampal tail compared with HC. Those with nonAD_Epi demonstrated greater left–to-right asymmetry in the hippocampal head compared with both nonAD_NoEpi and HC. AD_NoEpi had an asymmetrically smaller left hippocampal head and right amygdala than HC. We found no group differences in volume asymmetries. Our study found left smaller than right hippocampal head asymmetry in non-Alzheimer’s dementia with epilepsy and left smaller than right hippocampal tail asymmetry in Alzheimer’s disease with epilepsy. These findings suggest that hippocampal shape asymmetry may serve as a neuroimaging correlate of epilepsy in ADRD.

  • Open Access

    The use of memantine for prevention of Alzheimer's disease: Pilot feasibility study rationale and protocol

    by Anna M. Arp, George S. Bloom, Anelyssa D'ABreu, Amy Fansler, Kimberlee Meegan, Sarah Ratcliffe, Jaideep Kapur, Carol Manning

  • Open Access

    Lactate receptor HCAR1 in neonatal hypoxic–ischemic seizures

    by Jennifer Burnsed, Angelina June, Maria Marlicz, Emmy Zucker, Ellie Kain‐Kuzniewski, Hannah Mulhern, Leanne Maharaj, John Williamson, Chengsan Sun, Suchitra Joshi, et al.

    Hydroxycarboxylic acid receptor 1 (HCAR1) is a G‐protein‐coupled lactate receptor expressed in the brain and plays a role in neuronal excitability and repair after injury. Hypoxic–ischemic encephalopathy (HIE) is the most common cause of brain injury and seizures in term neonates. The goal of this study was to describe HCAR1 expression and function in the neonatal brain and understand its role in HIE‐associated seizures. HCAR1 expression was measured using quantitative reverse transcriptase polymerase chain reaction in postnatal day (p)10–50 mice. Neuronal properties and spontaneous excitatory postsynaptic currents (sEPSCs) were measured in hippocampal principal neurons from HCAR1 knockout and wild‐type mice when exposed to lactate. p10 HCAR1 knockout and wild‐type mice were exposed to hypoxia–ischemia (HI) and underwent electroencephalography to compare seizure burden. HCAR1 was expressed at p10 at similar levels to adults. Lactate decreased amplitudes and sEPSC frequency in wild‐type but not HCAR1 knockout mice. After HI, HCAR1 knockout mice had higher seizure burden and behavioral seizure scores than wild‐type mice. HCAR1 is expressed on neurons and plays a role in neuronal excitability and seizures in the neonatal brain.


  • Open Access

    Hydroxycarboxylic Acid Receptor 2 Mediates β‐hydroxybutyrate's Antiseizure Effect in Mice

    by Soudabeh Naderi, John Williamson, Huayu Sun, Suchitra Joshi, Rachel Jane Spera, Savaira Zaib, Supriya Sharma, Chengsan Sun, Andrey Brodovskiy, Ifrah Zawar, et al.

    Objective: The ketogenic diet, a high‐fat, low‐carbohydrate regimen, is often used to treat drug‐resistant seizures and is being studied for Alzheimer's disease and other neuropsychiatric disorders. However, its mechanism of action remains unclear. β‐hydroxybutyrate, a primary circulating ketone body produced by the ketogenic diet, may mediate its effects on seizures by binding to a recently identified Gi‐coupled receptor: hydrocarboxylic acid receptor 2 (HCAR2). Methods: RNAscope in situ hybridization assay and real‐time quantitative polymerase chain reaction were used to assess HCAR2 expression in the mouse brain. We generated HCAR2 − / − using the CRISPR‐Cas technique on an S129 mouse background. Whole‐cell current‐clamp was performed to measure the passive and active membrane properties of hippocampal dentate granule cells. The voltage‐clamp was performed to record synaptic currents. Two complementary in vivo mouse models—continuous hippocampal stimulation to induce status epilepticus (SE) and kindling—were used to induce seizures. Results: HCAR2 was localized in dentate granule cells and microglia. In mice with HCAR2, β‐hydroxybutyrate reduced neuronal excitability by hyperpolarizing the resting membrane potential, raising the action potential threshold, and reducing the firing frequency of dentate granule cells. β‐hydroxybutyrate suppressed excitatory synaptic transmission. These effects were nullified in HCAR2 − / − mice. HCAR2 − / − mice showed no cognitive impairment. Moreover, β‐hydroxybutyrate did not affect seizures in HCAR2 − / − mice. However, it diminished both the duration and severity of seizures in HCAR2 + / + mice. Interpretation: These findings demonstrate that HCAR2 mediates β‐hydroxybutyrate's antiseizure effects by regulating neuronal excitability and synaptic transmission. These studies propose a new mechanism for the antiseizure action of the ketogenic diet. ANN NEUROL 2026;99:809–824


  • Open Access

    Respiratory dysfunction and fatal apnea during pilocarpine‐induced status epilepticus

    by Chengsan Sun, Rachel Spera, John M. Williamson, Suchitra Joshi, Bhavya Guduru, Harini Ganabady, Jaideep Kapur

    Objective: Status epilepticus (SE) is second only to sudden unexpected death in epilepsy as a cause of seizure‐related mortality. The progression of respiratory dysfunction during experimental SE remains poorly characterized. We investigated how pilocarpine‐induced SE affects respiration in mice. Methods: We performed simultaneous plethysmographic, electroencephalographic, and electrocardiographic recordings in mice administered pilocarpine at 200, 240, or 280 mg/kg. We analyzed seizure progression, respiratory rate, ventilation, inspiratory/expiratory timing, and survival. Results: Higher pilocarpine doses resulted in shorter latency to SE and increased mortality. Across all doses, respiratory frequency and ventilation increased from baseline through early and established SE. There were respiratory abnormalities during SE, apneustic respiration, and pathological sigh, each associated with prolonged inspiration and expiration compared to eupneic respiration. Abnormal respiratory events occurred with similar frequency in both fatal and surviving animals. Death occurred during established SE. The sequence of events leading to death was a severe seizure, ending with tonic extension followed by terminal apnea. Seizure activity continued after apnea onset, followed by electrocerebral silence. Cardiac rhythm persisted beyond brain inactivity, gradually slowing to terminal arrest. Significance: Pilocarpine‐induced SE leads to progressive, dose‐dependent respiratory disturbances culminating in fatal apnea. These findings highlight the critical role of respiratory failure in SE‐related death and underscore the need for real‐time respiratory monitoring and early intervention during SE.